JPH09505805A - スーパーオキシドディスムターゼおよびその模倣物 - Google Patents
スーパーオキシドディスムターゼおよびその模倣物Info
- Publication number
- JPH09505805A JPH09505805A JP7512010A JP51201095A JPH09505805A JP H09505805 A JPH09505805 A JP H09505805A JP 7512010 A JP7512010 A JP 7512010A JP 51201095 A JP51201095 A JP 51201095A JP H09505805 A JPH09505805 A JP H09505805A
- Authority
- JP
- Japan
- Prior art keywords
- sod
- arg
- mimetic
- lys
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.窒素含有大環状成分および細胞表面もしくは細胞外マトリックス標的化成分 、またはそれらの薬学的に許容される塩を含む、スーパーオキシドディスムター ゼの模倣物。 2.前記大環状成分がポルフィリンである、請求項1記載の模倣物。 3.前記ポルフィリンがテトラキス(4−安息香酸)ポルフィリンである、請求 項1記載の模倣物。 4.次式: [式中、 ここで、Xはハロゲンであり、Yはアルキル基であり、 R2は、結合、−(CY'2)n -、−(CY'2−CY'=CY')n -、−(CY'2− CY'2−CH=CH)n -、−(CY'=CY')n - または 1から8であり; R3は、−Y"、−OH、−NH2、−N+(Y")3、−COOH、−COO-、− SO3H、−SO3 -、−C−PO3H2または−C−PO3H-であり、ここでY"は アルキル基であり; R3はY”ではなく、 R3は−Y"、−N+(Y")3またはCOOHではない] のスーパーオキシドディスムターゼ模倣物またはその薬学的に許容される塩。 5.前記模倣物が、マンガン、銅および鉄からなる群より選択される金属に錯体 化している、請求項1または4に記載の模倣物。 6.前記標的化成分が、 (NH−CH2−CH2−NH)n−H[式中、nは1から6である]; NH2−His Arg His His Pro Arg Glu Met Lys Lys Arg Val Glu Asp Leu−COOH; NH2−Arg Glu His Ser Glu Arg Lys Lys Arg Arg Arg Glu Ser Glu Cys Lys Ala Ala−COOH; NH2−Arg Glu His Ser Glu Arg Lys Lys Arg Arg Arg Glu−CO OH; NH2−Arg Glu His Ser Glu Arg Lys Lys Arg Arg Arg Ala−CO OH; NH2−Arg Glu His Ser Glu Arg Lys Lys Arg Arg Arg Ala Ser Glu Cys Lys Ala Ala−COOH; NH2−Arg Glu His Ser Glu Arg Lys Lys Arg Arg Arg Glu Ser Glu Ala Lys Ala Ala−COOH; NH2−Arg Glu His Ser Glu Arg Lys Lys Arg Arg Arg Glu Ser Glu Cys Ala Ala Ala−COOH; NH2−Arg Glu His Ser Glu Arg Lys Lys Arg Arg Arg Ala Ser Ala Cys Lys Ala Ala−COOH; NH2−Arg Glu His Ser Glu Arg Lys Lys Arg Arg Arg Ala Ser Glu Cys Ala Ala Ala−COOH; NH2−Arg Glu His Ser Glu Arg Lys Lys Gly Arg Arg Ala Ser Glu Cys Ala Ala Ala−COOH;および (Arg)n、(Lys)n、(Arg)n(Lys)n、(ArgLys)n、(LysArg)n、 (LysLysArgArg)n[式中、nは1から12である] からなる群より選択される、請求項1記載の模倣物。 7.細胞をスーパーオキシドラジカル誘導毒性から防御する方法であって、前記 細胞を、無毒性量の前記防御を達成するのに十分な量の請求項1記載の模倣物ま たは次式: [式中、 ここで、Xはハロゲンであり、Yはアルキル基であり、 R2は、結合、−(CY'2)n -、−(CY'2−CY'=CY')n -、−(CY'2− CY'2−CH=CH)n -、−(CY'=CY')n - または 1から8であり; R3は、−Y"、−OH、−NH2、−N+(Y")3、−COOH、−COO-、− SO3H、−SO3 -、−C−PO3H2または−C−PO3H-であり、ここでY"は アルキル基である] の模倣物であって、マンガン、銅および鉄からなる群より選択される金属に錯体 化していてもよい模倣物またはその薬学的に許容される塩と接触させることを含 む方法。。 8.前記模倣物がマンガン、銅および鉄からなる群より選択される金属に錯体化 している、請求項7記載の方法。 9.前記細胞が哺乳動物細胞である、請求項7記載の方法。 10.前記細胞が植物細胞である、請求項7記載の方法。 11.物質の酸化およびそれに続くO2 -の形成に起因する損傷を阻害する方法で あって、前記物質を、無毒性量の前記阻害を達成するのに十分な量の請求項1記 載の模倣物または次式: [式中、 ここで、Xはハロゲンであり、Yはアルキル基であり、 R2は、結合、−(CY'2)n -、−(CY'2−CY'=CY')n -、−(CY'2− CY'2−CH=CH)n -、−(CY'=CY')n - または 1から8であり; R3は、−Y"、−OH、−NH2、−N+(Y")3、−COOH、−COO-、− SO3H、−SO3 -、−C−PO3H2または−C−PO3H-であり、ここでY"は アルキル基である] の模倣物またはその薬学的に許容される塩と接触させることを含む方法。 12.前記模倣物がマンガン、銅および鉄からなる群より選択される金属に錯体 化している、請求項11記載の方法。 13.スーパーオキシドラジカル誘導性のNO・の分解に起因する患者の病理学 的状態を治療する方法であって、前記患者に、有効量のスーパーオキシドディス ムターゼ活性を有する化合物を、前記治療が達成される条件下で投与することを 含む方法。 14.前記化合物が蛋白質性化合物である、請求項13記載の方法。 15.前記化合物がSODの模倣物である、請求項13記載の方法。 16.前記模倣物がポルフィリン環含有模倣物である、請求項15記載の方法。 17.グリコサミノグリカン(GAG)結合成分が前記模倣物に結合している、 請求項15記載の方法。 18.前記GAG結合成分が、ヘパリン結合親和性を有するEC−SODのC末 端もしくはその部分に対応する、請求項17記載の方法。 19.前記GAG結合成分が、正に荷電したアミノ酸の繰り返しを含む、請求項 17記載の方法。 20.そのような治療を必要とする患者において炎症性状態を治療する方法であ って、前記患者に有効量のSODもしくはEC−SODの模倣物を前記治療が達 成される条件下で投与することを含む方法。 21.GAG結合成分が前記模倣物に結合している、請求項20記載の方法。 22.前記GAG結合成分が、ヘパリン結合親和性を有するEC−SODのC末 端もしくはその部分に対応する、請求項21記載の方法。 23.前記GAG結合成分が、正に荷電したアミノ酸の繰り返しを含む、請求項 21記載の方法。 24.そのような治療を必要とする患者において異常な平滑筋機能に起因する疾 患を治療する方法であって、前記患者に有効量のSODもしくはEC−SODの 模倣物を前記治療が達成される条件下で投与することを含む方法。 25.GAG結合成分が前記模倣物に結合している、請求項24記載の方法。 26.前記GAG結合成分が、ヘパリン結合親和性を有するEC−SODのC末 端もしくはその部分に対応する、請求項25記載の方法。 27.前記GAG結合成分が、正に荷電したアミノ酸の繰り返しを含む、請求項 25記載の方法。 28.それに結合したGAG結合成分を有するEC−SODの模倣物。 29.前記結合成分が、ヘパリン結合親和性を有するEC−SODのC末端もし くはその部分に対応する、請求項28記載の模倣物。 30.前記GAG結合成分が、正に荷電したアミノ酸の繰り返しを含む、請求項 28記載の模倣物。 31.請求項1、4または28に記載の模倣物および薬学的に許容される担体を 含む医薬組成物。 32.容器手段内に配置されている請求項1、4または28に記載の模倣物を含 むキット。 33.図24に示される配列もしくはその少なくとも18ヌクレオチド長の部分 を有する、単離されたEC−SOD遺伝子。 34.前記部分が前記遺伝子の非コーディング領域に対応する、請求項33載の 遺伝子。 35.細胞または組織のキサンチンオキシダーゼ活性を阻害する方法であって、 前記細胞または組織を、前記阻害が達成されるのに十分な量の請求項1記載の模 倣物または次式: [式中、 ここで、Xはハロゲンであり、Yはアルキル基であり、 R2は、結合、−(CY'2)n -、−(CY'2−CY'=CY')n -、−(CY'2−C Y'2−CH=CH)n -、−(CY'=CY')n - または 1から8であり; R3は、−Y"、−OH、−NH2、−N+(Y")3、−COOH、−COO-、− SO3H、−SO3 -、−C−PO3H2または−C−PO3H-であり、ここでY"は アルキル基である] の模倣物であって、マンガン、銅および鉄からなる群より選択される金属に錯体 化していてもよい模倣物またはその薬学的に許容される塩と接触させることを含 む方法。 36.前記病理学的状態が、前記患者の肺におけるものであり、前記投与が前記 患者の気道に対してなされ、かつ、前記化合物が細胞外スーパーオキシドディス ムターゼの組織特異性を有する、請求項13記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13620793A | 1993-10-15 | 1993-10-15 | |
US136,207 | 1993-10-15 | ||
PCT/US1994/011558 WO1995010185A1 (en) | 1993-10-15 | 1994-10-13 | Superoxide dismutase and mimetics thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09505805A true JPH09505805A (ja) | 1997-06-10 |
Family
ID=22471830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7512010A Ceased JPH09505805A (ja) | 1993-10-15 | 1994-10-13 | スーパーオキシドディスムターゼおよびその模倣物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5747026A (ja) |
EP (2) | EP1442747A1 (ja) |
JP (1) | JPH09505805A (ja) |
AT (1) | ATE291351T1 (ja) |
AU (1) | AU702596B2 (ja) |
CA (1) | CA2174236C (ja) |
DE (1) | DE69434313T2 (ja) |
ES (1) | ES2237753T3 (ja) |
WO (1) | WO1995010185A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002512989A (ja) * | 1998-04-24 | 2002-05-08 | デューク・ユニバーシティー | 置換ポルフィリン |
JP2010229145A (ja) * | 1997-11-03 | 2010-10-14 | Duke Univ | 置換されたポルフィリン類 |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747026A (en) * | 1993-10-15 | 1998-05-05 | University Of Alabama At Birmingham Research Foundation | Antioxidants |
US6127356A (en) * | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
US5994339A (en) * | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
AU3758695A (en) * | 1994-09-20 | 1996-04-09 | Duke University | Oxidoreductase activity of manganic porphyrins |
JPH11509180A (ja) * | 1995-06-07 | 1999-08-17 | デューク・ユニバーシティ | 酸化体脱除剤 |
CA2229781A1 (en) * | 1995-08-17 | 1997-02-27 | Monsanto Company | Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands |
CA2183834C (en) * | 1995-08-22 | 2003-09-09 | Hiroshi Maeda | Antihypertensive agents containing pyrazolopyrimidine derivatives |
CA2249011A1 (en) * | 1996-03-13 | 1997-09-18 | Monsanto Company | Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
WO2000009111A2 (en) * | 1998-08-11 | 2000-02-24 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Inhibitors of amyloid formation |
GB9817845D0 (en) | 1998-08-17 | 1998-10-14 | Glaxo Group Ltd | Chemical compounds |
WO2000023568A2 (en) * | 1998-10-06 | 2000-04-27 | Albert Einstein College Of Medicine Of Yeshiva University | Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells |
US6695830B2 (en) * | 1999-01-15 | 2004-02-24 | Scimed Life Systems, Inc. | Method for delivering medication into an arterial wall for prevention of restenosis |
US6210392B1 (en) * | 1999-01-15 | 2001-04-03 | Interventional Technologies, Inc. | Method for treating a wall of a blood vessel |
DK1616869T3 (da) * | 1999-01-25 | 2012-05-07 | Nat Jewish Health | Substituerede porphyriner og deres terapeutiske anvendelse |
IT1306716B1 (it) * | 1999-06-21 | 2001-10-02 | Mendes S U R L | Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori. |
SE9903985D0 (sv) * | 1999-11-03 | 1999-11-03 | Aga Ab | Use of nitric oxide |
FR2806911B1 (fr) * | 2000-03-28 | 2003-01-10 | Univ Rene Descartes | Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires |
US6403788B1 (en) | 2000-07-11 | 2002-06-11 | Eukarion, Inc. | Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species |
WO2002022573A2 (en) * | 2000-09-15 | 2002-03-21 | The Scripps Research Institute | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
US20020072512A1 (en) * | 2000-12-08 | 2002-06-13 | Metaphore Pharmaceuticals, Inc | Method of preventing and treating HIV-mediated central nervous system damage |
ATE439134T1 (de) * | 2001-01-19 | 2009-08-15 | Nat Jewish Med & Res Center | Medikament zum schutz in der radiotherapie |
WO2002058686A2 (en) * | 2001-01-26 | 2002-08-01 | Metaphore Pharmaceuticals, Inc. | Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
AU2002312194B8 (en) * | 2001-06-01 | 2008-05-15 | Aeolus Sciences, Inc. | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
US20050129680A1 (en) * | 2001-09-17 | 2005-06-16 | Paul Wentworth | Antimicrobial activity of antibodies |
US20040116350A1 (en) * | 2001-09-17 | 2004-06-17 | Paul Wentworth Jr | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
US20040157280A1 (en) * | 2001-09-17 | 2004-08-12 | Paul Wentworth | Antibody mediated ozone generation |
AU2003216400A1 (en) | 2002-02-22 | 2003-09-09 | The Curators Of The University Of Missouri | Compounds for treatment of copper overload |
WO2003103680A1 (en) * | 2002-06-07 | 2003-12-18 | Duke University | Substituted porphyrins |
CA2505923A1 (en) * | 2002-11-14 | 2004-05-27 | Novartis Ag | Antibody-or neutrophil-mediated ozone generation |
PT2604286E (pt) | 2003-05-01 | 2014-11-28 | Cornell Res Foundation Inc | Método e complexos transportadores para entregar moléculas às células |
MXPA06011244A (es) | 2004-03-29 | 2007-04-13 | Inotek Pharmaceuticals Corp | Compuestos de porfirina sustituida por piridilo, y metodos de uso de los mismos. |
WO2008018932A2 (en) | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
EP2300032A4 (en) | 2008-05-13 | 2012-12-05 | Univ Kansas | MARKER PRESENTING IN THE FORM OF A MAP PEPTIDE (METAL ABSTRACTION PEPTIDE) AND ASSOCIATED METHODS |
EP2732817B1 (en) | 2008-05-23 | 2016-08-24 | National Jewish Health | A compound for use in treating injury associated with exposure to phosgene or chlorine gas |
JP4891367B2 (ja) | 2009-05-21 | 2012-03-07 | トヨタ自動車株式会社 | 溶媒組成物 |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
WO2013181461A2 (en) | 2012-06-01 | 2013-12-05 | University Of Kansas | Metal abstraction peptide with superoxide dismutase activity |
CN104190927B (zh) | 2014-08-11 | 2016-05-18 | 苏州大学 | 一种同步送粉空间激光加工与三维成形方法及装置 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4758422A (en) * | 1985-01-04 | 1988-07-19 | Salutar Inc. | Ferrioxamine paramagnetic contrast agents for MR imaging |
ATE78158T1 (de) * | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
DK402785D0 (da) * | 1985-09-03 | 1985-09-03 | Syn Tek Ab | Fremgangsmaade til fremstilling af et enzym |
EP0282899B1 (de) * | 1987-03-14 | 1996-01-10 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Humane Mangan-Superoxiddismutase (hMn-SOD) |
US5227405A (en) * | 1987-03-31 | 1993-07-13 | Duke University | Superoxide dismutase mimic |
US5223538A (en) * | 1987-03-31 | 1993-06-29 | Duke University | Superoxide dismutase mimic |
US5171680A (en) * | 1988-06-14 | 1992-12-15 | Chiron Corporation | Superoxide dismutase analogs having novel binding properties |
DE69027383T2 (de) * | 1989-03-06 | 1996-11-14 | Suntory Ltd | Neue superoxyd-dismutase |
DK455789D0 (da) * | 1989-09-15 | 1989-09-15 | Symbicom Ab | Polypeptid |
EP0424033A3 (en) * | 1989-10-19 | 1991-07-31 | Pola Chemical Industries Inc | External skin preparation |
EP0462836A3 (en) * | 1990-06-20 | 1992-08-26 | Mitsui Toatsu Chemicals, Inc. | Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme |
US5217966A (en) * | 1990-09-13 | 1993-06-08 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
US5202317A (en) * | 1990-09-13 | 1993-04-13 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
WO1992007935A1 (en) * | 1990-11-01 | 1992-05-14 | The Scripps Research Institute | Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions |
DE69224839T2 (de) * | 1991-07-19 | 1998-10-08 | Monsanto Co | Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren. |
US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5747026A (en) * | 1993-10-15 | 1998-05-05 | University Of Alabama At Birmingham Research Foundation | Antioxidants |
WO2000023568A2 (en) * | 1998-10-06 | 2000-04-27 | Albert Einstein College Of Medicine Of Yeshiva University | Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells |
DK1616869T3 (da) * | 1999-01-25 | 2012-05-07 | Nat Jewish Health | Substituerede porphyriner og deres terapeutiske anvendelse |
US6448239B1 (en) * | 1999-06-03 | 2002-09-10 | Trustees Of Princeton University | Peroxynitrite decomposition catalysts and methods of use thereof |
-
1994
- 1994-02-02 US US08/190,504 patent/US5747026A/en not_active Expired - Lifetime
- 1994-10-13 JP JP7512010A patent/JPH09505805A/ja not_active Ceased
- 1994-10-13 EP EP04010434A patent/EP1442747A1/en not_active Withdrawn
- 1994-10-13 DE DE69434313T patent/DE69434313T2/de not_active Expired - Lifetime
- 1994-10-13 WO PCT/US1994/011558 patent/WO1995010185A1/en active IP Right Grant
- 1994-10-13 ES ES94930729T patent/ES2237753T3/es not_active Expired - Lifetime
- 1994-10-13 CA CA002174236A patent/CA2174236C/en not_active Expired - Lifetime
- 1994-10-13 AU AU79763/94A patent/AU702596B2/en not_active Expired
- 1994-10-13 AT AT94930729T patent/ATE291351T1/de not_active IP Right Cessation
- 1994-10-13 EP EP94930729A patent/EP0723398B1/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010229145A (ja) * | 1997-11-03 | 2010-10-14 | Duke Univ | 置換されたポルフィリン類 |
JP2002512989A (ja) * | 1998-04-24 | 2002-05-08 | デューク・ユニバーシティー | 置換ポルフィリン |
JP4648542B2 (ja) * | 1998-04-24 | 2011-03-09 | デューク ユニバーシティ | 置換ポルフィリン |
Also Published As
Publication number | Publication date |
---|---|
EP0723398A1 (en) | 1996-07-31 |
DE69434313D1 (de) | 2005-04-28 |
ATE291351T1 (de) | 2005-04-15 |
AU702596B2 (en) | 1999-02-25 |
DE69434313T2 (de) | 2006-03-30 |
US5747026A (en) | 1998-05-05 |
CA2174236A1 (en) | 1995-04-20 |
EP0723398A4 (en) | 1999-03-24 |
WO1995010185A1 (en) | 1995-04-20 |
ES2237753T3 (es) | 2005-08-01 |
CA2174236C (en) | 2008-02-12 |
EP0723398B1 (en) | 2005-03-23 |
AU7976394A (en) | 1995-05-04 |
EP1442747A1 (en) | 2004-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09505805A (ja) | スーパーオキシドディスムターゼおよびその模倣物 | |
US5994339A (en) | Oxidant scavengers | |
US6583132B1 (en) | Oxidant scavengers | |
CA2223407C (en) | Oxidant scavengers | |
Esposito et al. | Mitochondrial oxidative stress in mice lacking the glutathione peroxidase-1 gene | |
EP0954330B1 (en) | Intestinal trefoil proteins | |
Wang et al. | Hypotension in transgenic mice overexpressing human bradykinin B2 receptor | |
US11141456B2 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
Waheed et al. | Membrane associated carbonic anhydrase IV (CA IV): a personal and historical perspective | |
Parajuli et al. | Generation and characterization of a novel kidney-specific manganese superoxide dismutase knockout mouse | |
EA027336B1 (ru) | Ингибирующие апоптоз фрагменты белка daxx, их пептидомиметики, конъюгаты и композиции и их применение | |
Jiang et al. | Generation and phenotypic analysis of mice lacking all urea transporters | |
Mao et al. | Critical involvement of lysyl oxidase in seizure-induced neuronal damage through ERK-Alox5-dependent ferroptosis and its therapeutic implications | |
Valerio Jr | Mammalian iron metabolism | |
Rahman et al. | Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury | |
AU769217B2 (en) | Oxidant scavengers | |
Oury | Extracellular superoxide dismutase and nitric oxide: Transgenic and immunocytochemical studies | |
CA2614621A1 (en) | Superoxide dismutase and mimetics thereof | |
US20180221454A1 (en) | Thioredoxin, thioredoxin peptides or derivatives for treatment of age-related hypertension | |
Tian et al. | An HSV-TK transgenic mouse model to evaluate elimination of fibroblasts for fibrosis therapy | |
WO2009149201A1 (en) | Methods of treatment for pulmonary fibrosis | |
AU2004201624A1 (en) | Oxidant Scavengers | |
EP1546362B1 (en) | Apolipoprotein e stable folding intermediate and methods of use thereof | |
Ledoux | The molecular basis of prolidase deficiency | |
Lyons | Studies of the metal binding properties and reactivity of yeast copper, zinc superoxide dismutase, the effect of Lys7p on these properties, and the implications for amyotrophic lateral sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050726 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051025 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051212 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060313 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060418 |